Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Size: px

Start display at page:

Download "Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy"

Amberlynn Chase
6 years ago
Views:

1 Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal Methotrexate for CNS Prophylaxis in GTN 266 Gynaecology PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) 267 Gynaecology Two Day Etoposide CISplatin (EP) 16/02/ Gastrointestinal CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation -Herskovic Regimen 462 Sarcoma Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX) 21 s 464 Skin/Melanoma Dacarbazine 10/02/ Gastrointestinal Nab-PACLitaxel (Abraxane ) and Gemcitabine 28 07/02/ Breast Trastuzumab (IV) Monotherapy 7 s 207 Gastrointestinal Cetuximab Monotherapy-7 s Head & Neck Cetuximab Monotherapy-7 s 246 Gynaecology Methotrexate 8 Charing Cross Regimen 247 Gynaecology DACTINomycin 248 Gynaecology EMA/CO 264 Gynaecology Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) 437 Genitourinary TICE -Autologous Conditioning Germ Cell Tumour Regimen 28/01/ Crizotinib Monotherapy 27/01/ Crizotinib Monotherapy 26/01/ Crizotinib Monotherapy 18/12/ Myeloma Dose Adjusted R-EPOCH CARBOplatin (AUC7) and Etoposide- Autologous 453 Genitourinary Conditioning Germ Cell Tumour Regimen CISplatin (50mg/m2) Etoposide (100mg/m2) and 456 Thoracic Radiotherapy (TRT) /12/ Genitourinary Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) -14 Days 338 Genitourinary Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) -28 Days 339 Vinorelbine and CISplatin -21 s 06/12/ Skin/Melanoma Vemurafenib Monotherapy

2 06/12/ CARBOplatin (AUC5) and Etoposide 100mg/m Gastrointestinal Gemcitabine (1000mg/m2) Monotherapy Gastrointestinal Gemcitabine (1000mg/m2) Monotherapy - 28 Gemcitabine (1000mg/m2) Monotherapy Genitourinary Bleomycin, Etoposide and CISplatin 301 Genitourinary Etoposide and CISplatin 20mg/m2 (EP) CISplatin (40mg/m2) Weekly with Radiotherapy 385 Genitourinary (RT) CISplatin (40mg/m2) Weekly with Radiotherapy Gynaecology (RT) CISplatin (40mg/m2) Weekly with Radiotherapy Head & Neck (RT) DOXOrubicin (25mg/m2/) and CISplatin 420 Sarcoma (100mg/m2) - 21 cycle 17/11/ Myeloma R-CODOX-M (Patients less than or equal to 65 years) 399 Myeloma R-IVAC (Patients less than or equal to 65 years) 403 Myeloma R-CODOX-M (Patients greater than 65 years) 404 Myeloma R-IVAC (Patients greater than 65 years) 450 Genitourinary 5-Fluorouracil and mitomycin Chemoradiation 451 Gastrointestinal 5-Fluorouracil (4 ) and mitomycin Chemoradiation 15/11/ Breast EriBULlin Monotherapy 265 Breast 5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) 269 Breast 5-Fluorouracil, epirubicin 50 and Cyclophosphamide (FEC50) 278 Breast Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 followed by PACLitaxel (175) 14 (DD AC-T) 281 Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Genitourinary Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) - 28

3 15/11/ Gynaecology Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) - 21 Gemcitabine + CARBOplatin (AUC 4) - 21s 310 Genitourinary Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) - 21 Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Gastrointestinal Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) /11/ Gynaecology Olaparib Monotherapy 01/11/ Skin/Melanoma Vismodegib Monotherapy 424 Myeloma Obinutuzumab and Bendamustine -28 cycle 425 Myeloma Obinutuzumab Maintenance following O-Bendamustine therapy 26/10/ Neuro-oncology Procarbazine Lomustine and VinCRIStine (PCV) 23/10/ Breast DOXOrubicin, Cyclophosphamide (AC 60/600) 21 followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) 433 Breast Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) 445 Genitourinary Pazopanib Sarcoma Pazopanib 446 Gastrointestinal Bevacizamab 5mg/kg and Modified FOLFOX Gastrointestinal Panitumumab 6mg/kg and Modified FOLFOX Gastrointestinal Panitumumab 6mg/kg and FOLFIRI Gastrointestinal Bevacizumab 5mg/kg and FOLFIRI 14 s 09/10/ Genitourinary Nivolulmab Monotherapy Myeloma Nivolulmab Monotherapy Skin/Melanoma Nivolumab Monotherapy 431 Skin/Melanoma Nivolumab Ipilimumab Combination 06/10/ Gastrointestinal FLOT /10/ Alectinib Monotherapy 29/09/ Breast CARBOplatin (AUC4-6) Monotherapy-21 s Gynaecology CARBOplatin (AUC4-6) Monotherapy-21 s 27/09/ Breast CARBOplatin Monotherapy-28 s Gynaecology CARBOplatin (AUC4-6) Monotherapy-28 s

4 27/09/ Breast DOXOrubicin and Cyclophosphamide 20/09/ Breast Trastuzumab Emtansine (Kadcyla ) - 21 s 255 Myeloma Pixantrone 258 Breast DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 s 272 Breast Trastuzumab Subcutaneous 21 s- Metastatic Breast Carcinoma 277 Myeloma Siltuximab Monotherapy 279 CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) CISplatin (75mg/m2) + Etoposide Breast Trastuzumab SC 21 s-early Breast Cancer 286 Myeloma Obinutuzumab and Chlorambucil 11/09/ Leukaemia/BMT Decitabine Monotherapy AML (28 cycle) 296 Leukaemia/BMT Ibrutinib Therap (CLL/ Waldenstrom's Macroglobulinaemia) 08/09/ Myeloma Ibrutinib Therap (Mantly Cell Lymphoma) 28/07/ Leukaemia/BMT DA(60/100) 3+10: Course 1 Induction (AML-17) 360 Leukaemia/BMT DA (50/100) (3+8) Course 2 Induction (AML-17) 364 Leukaemia/BMT Intermediate Dose Cytarabine 365 Leukaemia/BMT High Dose Cytarabine 395 Myeloma (R**)-DHAP 397 Myeloma (R**)-ICE ((rituximab), Ifosfamide, CARBOplatin and Etoposide) 408 Myeloma BEAM Autologous Transplant Conditioning Protocol 429 Gastrointestinal epirubicin, Oxaliplatin and 5-FU (EOF) /07/ Gastrointestinal CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks 423 Breast DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) - 21 cycle 427 Gastrointestinal Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen 428 Gastrointestinal QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly

5 07/07/ Breast Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 s 03/07/ Leukaemia/BMT Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction 01/07/ Gastrointestinal epirubicin, Oxaliplatin and Capecitabine (EOX) 240 Gastrointestinal epirubicin, CISplatin and 5-FU (ECF) 20/06/ Breast Oral Vinorelbine Monotherapy-7s Oral Vinorelbine Monotherapy-7s 260 Breast DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel (AC-T) 262 Breast epirubicin 90 + Cyclophosphamide (EC90) 263 Breast epirubicin 75 + Cyclophosphamide (EC75) 30/05/ Breast Trastuzumab (IV) Monotherapy 21 s 202 Breast DOCEtaxel Monotherapy 100mg/m2 21 cycle 203 Genitourinary DOCEtaxel Monotherapy 75mg/m2 21 cycle DOCEtaxel Monotherapy 75mg/m2 21 cycle 211 Gastrointestinal Bevacizumab 5mg/kg - 14 s 212 Breast Bevacizumab 10mg/kg-14s Gastrointestinal Bevacizumab 10mg/kg-14s Genitourinary Bevacizumab 10mg/kg-14s Gynaecology Bevacizumab 10mg/kg-14s 214 Gastrointestinal Bevacizumab 7.5mg/kg-21s Bevacizumab 7.5mg/kg-21s 215 Breast Bevacizumab 15mg/kg - 21 s Gastrointestinal Bevacizumab 15mg/kg - 21 s Gynaecology Bevacizumab 15mg/kg - 21 s Bevacizumab 15mg/kg - 21 s 225 Gastrointestinal Panitumumab 6mg/kg 250 Breast DOCEtaxel /Cyclophosphamide (TC) /05/ Head & Neck Cetuximab (weekly), CISplatin 100mg/m2 and 5- FU 1000mg/m2/ - 21 cycle 418 Head & Neck Cetuximab (weekly), CARBOplatin AUC 5 and 5- FU 1000mg/m2/ - 21 cycle 419 Head & Neck CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) 421 Gastrointestinal 5-Fluorouracil 225mg/m2/ and Radiotherapy (RT)-Continuous infusion 7

6 02/05/ Myeloma 05/04/ Myeloma Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 rituximab and Bendamustine 15/03/ Head & Neck Lenvatinib 409 Myeloma R-CHOP-14 s 08/03/ Leukaemia/BMT 293 Myeloma 307 Myeloma 393 Myeloma 396 Myeloma Fludarabine, Cyclophosphamide and rituximab (FC IV+R) (*rituximab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) 21 s (R*)-CHOP 21 s Nordic Protocol CHOEP 21 s Fludarabine, Cyclophosphamide and rituximab (FC Oral+R) 410 Leukaemia/BMT 01/03/ Sarcoma Mifamurtide 101 Genitourinary Cabazitaxel and Prednisolone 209 Gastrointestinal Modified FOLFOX Gastrointestinal FOLFOX Erlotinib Monotherapy 226 Breast PACLitaxel Monotherapy 80mg/m2 7 Gastrointestinal PACLitaxel Monotherapy 80mg/m2 7 Gynaecology PACLitaxel Monotherapy 80mg/m Gastrointestinal FOLFIRI /02/ Nindetanib 382 Gastrointestinal Trifluridine and Tipiracil (Lonsurf ) 18/01/ Breast Lapatinib and Capecitabine 11/01/ Breast Capecitabine Monotherapy Gastrointestinal Capecitabine Monotherapy 217 Breast Lapatinib and Capecitabine 237 Skin/Melanoma Dabrafenib Monotherapy 242 Head & Neck Vandetanib Monotherapy 05/01/ Myeloma Idelalisib Monotherapy 389 Leukaemia/BMT Idelalisib and rituximab 390 Leukaemia/BMT Idelalisib and Ofatumumab 20/12/ Leukaemia/BMT Ponatinib 340 Ceritinib Monotherapy 384 Gastrointestinal Gemcitabine + Capecitabine 386 Gastrointestinal DOXOrubicin (60mg/m2) 387 Head & Neck CISplatin (100mg/m2) with Radiotherapy (RT) 388 Oral Etoposide

7 20/12/ Sarcoma DOXOrubicin (60) and Ifosfamide 392 Sarcoma DOXOrubicin (75) and Ifosfamide 15/12/ Genitourinary Radium /12/ Breast CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide -Triple Negative Breast Cancer 377 Breast Cylophosphamide (Oral) Methotrexate and 5- Fluorouracil (CMF) 378 Breast Cylophosphamide (IV) Methotrexate and 5- Fluorouracil (CMF) 28 Day 381 Breast Cylophosphamide (IV) Methotrexate and 5- Fluorouracil (CMF) 21 Day 16/11/ Breast Anastrozole Monotherapy 11/11/ Myeloma ABVD 361 Breast Fulvestrant 371 Breast Letrozole Monotherapy 374 Sarcoma Trabectedin Monotherapy 375 Gynaecology Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) 376 Breast Exemestane Monotherapy 380 Gastrointestinal epirubicin, CISplatin and Capecitabine (ECX) 01/11/ Gastrointestinal CISplatin and Teysuno-28 cycle 23/10/ Gastrointestinal FOLFIRI + Cetuximab 21/10/ Genitourinary Axitinib Monotherapy 253 Breast Tamoxifen Monotherapy 16/09/ Myeloma Pomalidomide and Dexamethasone 08/08/ Myeloma Bortezomib + Dexamethasone +Thalidomide (VTD)Induction 275 Myeloma Bortezomib, Melphalan and Prednisolone 299 Myeloma Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone Weekly 30/06/ Breast Pertuzumab + Trastuzumab + DOCEtaxel 233 Leukaemia/BMT Enzalutamide Monotherapy 27/06/ Leukaemia/BMT Brentuximab vedotin Monotherapy Myeloma Brentuximab vedotin Monotherapy 20/06/ Breast Pegylated Liposomal DOXOrubicin (CAELYX) 28 s Gynaecology Pegylated Liposomal DOXOrubicin (CAELYX)

8 20/06/ Gynaecology Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) 316 Breast Dose Dense DOXOrubicin, Cyclophosphamide followed by PACLitaxel (14 s) and Trastuzumab 330 Gastrointestinal Cetuximab (7 s) and Irinotecan (14 s) 331 Gastrointestinal Cetuximab (14 s) and Irinotecan (14 s) 332 Head & Neck CARBOplatin AUC (1.5) Chemoradiation - 7 s 334 Neuro-oncology Temozolomide with RT and Adjuvant 335 Sarcoma Imatinib Therpay-GIST 337 Genitourinary CISplatin, Methotrexate and Vinblastine 342 Neuro-oncology Temozolomide Recurrent 343 Vinorelbine and CISplatin -28 s 376 Breast Exemestane Monotherapy 09/06/ Skin/Melanoma Pembrolizumab 08/06/ Skin/Melanoma Ipilimumab Monotherapy 03/06/ Pemetrexed and CARBOplatin 321 Gastrointestinal Capecitabine/Oxaliplatin (XELOX) 325 Genitourinary Sunitinib 50mg Sarcoma Sunitnib 50mg 326 Genitourinary Temsirolimus Monotherapy 327 Neuroendocrine Sunitnib 37.5mg 329 Gastrointestinal FOLFIRINOX 03/05/ Leukaemia/BMT Bosutinib Monotherapy 229 Leukaemia/BMT Ruxolitinib Monotherapy 232 Leukaemia/BMT Intravenous Vinorelbine Intravenous Vinorelbine Monotherapy-7s 294 Gastrointestinal Sorafenib Genitourinary Sorafenib Head & Neck Sorafenib 313 Genitourinary DOCEtaxel Monotheray 50mg/m2 Monotherapy Head & Neck CISplatin/5-FU 315 Head & Neck Neoadjuvant DOCEtaxel/CISplatin/5-FU + Chemoradiation + Surgery 317 Pemetrexed and CISplatin 319 CARBOplatin + Oral Etoposide 320 Genitourinary Everolimus Monotherapy Neuroendocrine Everolimus Monotherapy 322 Breast Everolimus and Exemestane 323 Head & Neck DOCEtaxel/CISplatin/5-FU + Chemoradiation 324 Head & Neck DOCEtaxel/CISplatin/5-FU + Radiotherapy

9 15/04/ Genitourinary Abiraterone and Prednisolone 238 Gastrointestinal Aflibercept-14 s 08/04/ Gastrointestinal Irinotecan Monotherapy - 21 s 220 Gefitinib Monotherapy 222 Pemetrexed Monotherapy 230 Breast Nab-PACLitaxel (Abraxane) Monotherapy-21 cycle 303 Gynaecology CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 304 CARBOplatin (AUC6) and PACLitaxel 200mg/m2 308 Gynaecology CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 309 Weekly CARBOplatin and PACLitaxel with Radiotherapy 311 Gynaecology Topotecan Monotherapy-5 Topotecan Monotherapy Gynaecology Topotecan Monotherapy-Weekly

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin